Eupraxia Pharmaceuticals Inc (EPRX) - Total Assets
Based on the latest financial reports, Eupraxia Pharmaceuticals Inc (EPRX) holds total assets worth CA$128.50 Million CAD (≈ $92.95 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See EPRX total equity for net asset value and shareholders' equity analysis.
Eupraxia Pharmaceuticals Inc - Total Assets Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data.
Eupraxia Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Eupraxia Pharmaceuticals Inc's total assets of CA$128.50 Million consist of 68.6% current assets and 31.5% non-current assets.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 65.9% |
| Accounts Receivable | CA$228.87K | 0.5% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$424.92K | 0.9% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how Eupraxia Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see EPRX market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Eupraxia Pharmaceuticals Inc's current assets represent 68.6% of total assets in 2024, a decrease from 92.8% in 2017.
- Cash Position: Cash and equivalents constituted 65.9% of total assets in 2024, down from 68.3% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 0.9% of total assets.
Eupraxia Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Eupraxia Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
|
China | CN¥3.06 Billion |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333
|
China | CN¥2.31 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥819.45 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.16 Billion |
Eupraxia Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 23.98 | 3.08 | 0.05 |
| Quick Ratio | 23.98 | 3.08 | 0.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$121.88 Million | CA$6.68 Million | CA$-21.40 Million |
Eupraxia Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Eupraxia Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.45 |
| Latest Market Cap to Assets Ratio | 7.84 |
| Asset Growth Rate (YoY) | 88.0% |
| Total Assets | CA$50.24 Million |
| Market Capitalization | $393.86 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Eupraxia Pharmaceuticals Inc's assets at a significant premium (7.84x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Eupraxia Pharmaceuticals Inc's assets grew by 88.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Eupraxia Pharmaceuticals Inc (2017–2024)
The table below shows the annual total assets of Eupraxia Pharmaceuticals Inc from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CA$50.24 Million ≈ $36.34 Million |
+87.99% |
| 2023-12-31 | CA$26.72 Million ≈ $19.33 Million |
+3.27% |
| 2022-12-31 | CA$25.88 Million ≈ $18.72 Million |
-17.12% |
| 2021-12-31 | CA$31.22 Million ≈ $22.59 Million |
+2047.93% |
| 2020-12-31 | CA$1.45 Million ≈ $1.05 Million |
-55.75% |
| 2019-12-31 | CA$3.29 Million ≈ $2.38 Million |
+12.92% |
| 2018-12-31 | CA$2.91 Million ≈ $2.10 Million |
-50.20% |
| 2017-12-31 | CA$5.84 Million ≈ $4.23 Million |
-- |
About Eupraxia Pharmaceuticals Inc
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unm… Read more